PACIFIC EDGE LIMITED — Board/Management Information 2020

Oct 14, 2020

15 October 2020

==> picture [236 x 58] intentionally omitted <==

PEB ANNOUNCES EXECUTIVE TEAM CHANGES TO SUPPORT GROWTH

Pacific Edge Limited (NZX: PEB) is strengthening and expanding its executive team as the company positions itself for growth, following the recent commercial milestones in the multi-billion dollar US healthcare market.

Retirement of Jimmy Suttie

Senior Vice-President of Global Operations for Pacific Edge, Jimmy Suttie, has advised that he will be retiring mid2021 but will remain available to Pacific Edge on a part time contract basis as required. A plan has been put in place to ensure a seamless transition over this time.

Pacific Edge CEO, David Darling, said: “Jimmy joined Pacific Edge at a formative time when the company was defining and developing new molecular diagnostic products. He was an integral part of the new product and clinical teams leading the development of the commercial protocols, design and implementation of our high-throughput laboratories and teams of scientists, medical technologists, software coders and biostatisticians that enable the Pacific Edge business.

“He was an active member of the team developing the clinical evidence that underpins the commercialisation of our Cxbladder products and chair of Pacific Edge’s Publications team, which was responsible for the many scientific and clinical publications of which Jimmy was also an author on many. Jimmy has a long list of achievements and has been an integral part of many world-firsts as Pacific Edge has secured its place in the global medical technology arena.”

Strengthening of the Executive Team

Pacific Edge will add three new roles to the New Zealand executive team to support its growth aspirations – Chief Technical Officer (CTO), Chief Operating Officer (COO) and Chief Information Officer (CIO). An internal appointment has been made to the CTO role and Pacific Edge congratulates Justin Harvey on his successful appointment. Recruitment will shortly commence for the COO and CIO roles to ensure high quality candidates for these positions.

CEO, David Darling, said: “Pacific Edge has always operated with a very lean management team. We are now at an appropriate time in our company’s evolution to add strength to our team as we look to leverage the opportunities ahead of us.”

ENDS

For more information contact:

David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800

15 October 2020

==> picture [236 x 58] intentionally omitted <==

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.